FMR LLC filed a Form 4 with the SEC on November 12, 2026, disclosing four sales of Avalyn Pharma Inc. (NASDAQ:AVLN) common stock executed on November 9 and November 10, 2026, through F-Prime Capital Partners Healthcare Fund V LP.
Key Highlights
- Four sale transactions: FMR LLC disposed of a combined 228,454 shares of Avalyn Pharma common stock across two trading days, November 9 and November 10, 2026.
- Weighted average prices: The four transactions were executed at weighted average prices of $29.06, $29.75, $29.56, and $30.28, respectively, with individual trade prices ranging as low as $28.65 and as high as $30.62.
- Remaining beneficial ownership: Following the reported transactions, FMR LLC held 2,056,081 shares of Avalyn Pharma common stock indirectly through F-Prime Capital Partners Healthcare Fund V LP.
- 10% owner status: FMR LLC is identified in the filing as a 10% owner of Avalyn Pharma Inc.
- Indirect ownership structure: All reported shares are held indirectly through F-Prime Capital Partners Healthcare Fund V LP, whose general partner chain ultimately involves Impresa Management LLC as managing member.
- Johnson family control noted: According to the filing, members of the Johnson family, including Abigail P. Johnson, may be deemed to form a controlling group with respect to FMR LLC under the Investment Company Act of 1940.
FMR LLC Reduces Avalyn Pharma Position Over Two Days in November 2026
According to the filing, FMR LLC sold Avalyn Pharma common stock in four separate transactions on November 9 and November 10, 2026. On November 9, FMR LLC disposed of 173,661 shares at a weighted average price of $29.06, with individual trades ranging from $28.65 to $29.64, and an additional 1,339 shares at a weighted average price of $29.75, with trades ranging from $29.68 to $29.83. These two transactions reduced the reported beneficial ownership from a pre-filing position to 2,109,535 shares.
On November 10, the filing discloses two further sales: 5,565 shares at a weighted average price of $29.56, with trades ranging from $28.82 to $29.81, and 47,889 shares at a weighted average price of $30.28, with trades ranging from $29.82 to $30.62. After all four transactions, beneficial ownership stood at 2,056,081 shares, held indirectly through F-Prime Capital Partners Healthcare Fund V LP. The filing notes that the general partner of that fund is F-Prime Capital Partners Healthcare Advisors Fund V LP, which is solely managed by Impresa Management LLC.
The filing identifies Abigail P. Johnson as a Director, Chairman, and Chief Executive Officer of FMR LLC, and states that the Johnson family holds Series B voting common shares representing 49% of FMR LLC's voting power. All transactions are coded "S" (sale) in Table I of the Form 4. FMR LLC states in the filing that it "undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information" regarding the individual trade prices behind each weighted average.
What Was Disclosed
FMR LLC reported four sales of Avalyn Pharma Inc. (NASDAQ:AVLN) common stock on November 9-10, 2026, totaling 228,454 shares at weighted average prices between $29.06 and $30.28, leaving 2,056,081 shares held indirectly through F-Prime Capital Partners Healthcare Fund V LP.




Please wait processing your request...